Back to browse

EXP001945

Paper

Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in triple negative breast cancer cells (2021)

Peptide

GALA + CREKA (dual CPP) — GC-NP

Sequence: GALA: nan; CREKA: CREKA

RNA

siRNA

All experiment fields

Experiment Id EXP001945
Paper Co-delivery of EGFR and BRD4 siRNA by cell-penetrating peptides-modified redox-responsive complex in
Peptide GALA + CREKA (dual CPP) — GC-NP
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence yes
Peptide Concentration
Rna Concentration
Mixing Ratio N/P = 30 (optimal)
Formulation Format Electrostatic polyplex (PEG-SS-PEI/siRNA) with CPP (GALA and/or CREKA) modification
Formulation Components GC-NP: GALA-PEG-SS-PEI + CREKA-PEG-SS-PEI complexed with siRNA (siEGFR:siBRD4 = 1:1)
Size Nm 70.00
Zeta Mv 8.00
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells MDA-MB-231 (TNBC) for uptake/gene silencing/phenotype; HUVEC for biocompatibility
Animal Model
Administration Route
Output Type In vitro functional RNA effect: qRT-PCR + western blot (EGFR/PI3K/Akt/BRD4/c-Myc) and phenotypic assays
Output Value Synergistic inhibition of EGFR/PI3K/Akt and BRD4/c-Myc signaling; reduced proliferation (CCK-8), invasion (Transwell), and migration (wound healing) vs single-siRNA groups
Output Units
Output Notes Uptake quantified by confocal microscopy + flow cytometry with FAM-siRNA; lysosomal escape demonstrated by time-dependent decrease in LysoTracker colocalization (Pearson Rr decreases 0.76→0.52).
Toxicity Notes
Curation Notes